This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
We are delighted to share that Alisa Knapp, Chris Bakewell, Dan McGavock, Dave Duski, Erin Crockett, Greg Bell, Jim Donohue, Julia Rowe, Kim Schenk, Mike Tate,...
Infertility affects more than 17% of people of reproductive age globally, yet access to ART remains uneven and often out of reach.
Abhishek Kumar, Elaine Damato and Alice Kim present their poster titled “Staying Competitive in a Crowded Vaccines Market: Is There Room for a Third or Fourth...
Greg Bell is a panelist during the session titled “Navigating Life Sciences disputes. An arbitrator’s perspective.” For more information on this event, click...
